SK Life Science, Inc., announced that the FDA has accepted its investigational new drug (IND) application for SKL24741, for the treatment of epilepsy. SK life science will launch a Phase 1 clinical trial for SKL24741 in 2020.
While the exact mechanism of action is not yet fully understood, the antiepileptic effects of SKL24741 may result from its ability to reduce excitatory nerve activity by inhibiting voltage-gated sodium channels, which helps slow or stop misfiring of the brain’s electrical system that causes seizures. A range of in vitro studies have suggested that SKL24741 has higher affinity for the inactivated phase of these sodium channels, potentially allowing selective targeting of the pathological conditions of epilepsy. Preclinical in vivo studies have demonstrated efficacy in a variety of animal seizure models.